Phase I/II clinical trial demonstrates feasibility, safety and effectivity of CMV-pp65-specific donor T-cells for the treatment of refractory CMV reactivation after allogeneic stem cell transplantation

Author(s):
Jedema, I.; Balen, P. van; Halkes, C.J.M.; Egmond, E.H.M. van; Liempt, E.A.G. van; Veld, S.A.J.; Hoogstraten, C.; Meij, P.; Kersting, S.; Zwaginga, J.J.; Rauser, G.; Assenmacher, M.; Falkenburg, J.H.F.
Published
2018
Publication type
Other
Date issued
2018-09-01
Language
English
Publisher
NATURE PUBLISHING GROUP
hdl
1887/122092